Charting the Future Prostate Cancer Market Landscape
The prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new novel therapies. The launch of Zytiga (abiraterone acetate), Medivation/Astellas’ Xtandi (enzalutamide) and Algeta/Bayer’s Xofigo are set to trigger the global prostate cancer market to grow from .5 billion in 2012 to .7 billion in 2017.
Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top analyses the global prostate cancer market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top will allow you to:
Forecast analysis report
The forecast analysis report component of Consensus Outlook: Prostate Cancer delivers a rich analysis of product-level sales forecast data and of the future events that underpin these forecasts. The product of meticulous FirstWord research, the report’s historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
Prostate Cancer – Competition intensifies in race to the top combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed by research of analysts who have an unrivalled level of intimacy with the market, the players, their products, and their stratgies. Key features include:
Forecast data model
FirstWord’s Prostate Cancer forecast data model allows you to examine detailed Excel spreadsheets to quickly compare various market parameters including:
Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis every time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.
Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.
Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.
Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.
Table of Contents
for Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top [Published by FirstWord Pharma]
1. FirstWord Analysis Highlights
3.Prostate Cancer Marketplace
4.Key Prostate Cancer Developers
5.Prostate Cancer Class Dynamics
6.Zytiga (abiraterone acetate; Johnson & Johnson) forecast
7.Xtandi (enzalutamide; Medivation/Astellas) forecast
8.Xofigo (radium-223 dichloride; Algeta/Bayer) forecast
9.Taxotere (docetaxel; Sanofi) forecast
10.Jevtana (cabazitaxel; Sanofi) forecast
11.Provenge (sipuleucel-T; Dendreon) forecast
12.Casodex (bicalutamide; AstraZeneca) forecast
13.Lupron (leuprolide acetate; Takeda/Abbvie) forecast
14.Bone metastases therapies forecast
15.Pipeline therapy forecasts
|Title||Date Published||Price from||More Details|
|Diabetes -- KOL Insight and Consensus Outlook Modules|
IntroductionThe medium term: battle lines are drawnThe fundamental drivers of the global diabetes ma...
|01 May 2014 by FirstWord Pharma||USD $7,900||More Info|
|Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook|
IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
|20 Jan 2014 by FirstWord Pharma||USD $7,495||More Info|
|Consensus Outlook: Multiple Sclerosis|
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
|01 Dec 2013 by FirstWord Pharma||USD $4,995||More Info|
|Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook|
IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
|01 Dec 2013 by FirstWord Pharma||USD $4,995||More Info|
|Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules|
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
|12 Mar 2013 by FirstWord Pharma||USD $7,495||More Info|
|HIV -- KOL Insight and Consensus Outlook Modules|
IntroductionWhat do frontline clinicians really think about current HIV treatment pathways and what ...
|24 Feb 2013 by FirstWord Pharma||USD $7,495||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.